CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia

Oncology Reports

Volumn 9, Issue 3, 2002, Pages 653-655

  Tayeb, Mohammed T ^a,b   Clark, Caroline ^a   Sharp, Linda ^a   Haites, Neva E ^a   Rooney, Patrick H ^a   Murray, Graeme I ^a   Payne, Simon N L ^a   McLeod, Howard L ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UMM AL QURA UNIVERSITY   (Saudi Arabia)

Author keywords

Benign prostate; CYP3A4; Hyperplasia; Polymorphism; Prostate cancer

Indexed keywords

CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; MIXED FUNCTION OXIDASE;

ALLELE; ARTICLE; CASE CONTROL STUDY; GENETICS; GENOTYPE; HUMAN; MALE; PATHOLOGY; PROMOTER REGION; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RISK; RISK FACTOR;

ALLELES; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; ODDS RATIO; PROMOTER REGIONS (GENETICS); PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0036582834     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.3.653     Document Type: Article

References (12)

1. Howe HL, Wingo PA, Thum MJ, Ries LAG, Rosenberg HM, Feigal EG and Edwards BK: Annual report to the nation on the status of cancer, featuring cancers with recent increasing trends (1973 through 1998). J Natl Cancer Inst 93: 824-842, 2001. (Pubitemid 32586611)
2. Holund B: Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 14: 29-35, 1980.
3. Armenian HK, Lilienfeld AM, Diamond EL and Bross ID: Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. Lancet ii: 115-117, 1974.
4. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ and Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90: 1225-1229, 1998. (Pubitemid 28407089)
5. Ando Y, Tateishi T, Sekido Y, Yamamoto T, Satho T, Hasegawa Y, Kobayashi S, Katsumata Y, Shimokata K and Saito H: Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 91: 1587-1588, 1999.
6. Amirimani B, Walker AH, Weber BL and Rebbeck TR: RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 91: 1588-1590, 1999.
7. Rebbeck TR: More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 92: 76, 2000.
8. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G and Witte JS: Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 8: 901-905, 1999. (Pubitemid 29508726)
9. Curran S, McKay JA, McLeod HL and Murray GI: Laser capture pathol. Mol Pathol 53: 64-68, 2000.
10. Tayeb MT, Clark C, Ameyaw MM, Haites NE, Price Evans DA, Tariq M, Mobarek A, Ofori-Addi D and McLeod HL: CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 10: 753-756, 2000.
11. Armenian HK, Lilienfeld AM, Diamond EL and Bross ID: Epidemiologic characteristics of patients with prostatic neoplasms. Am J Epidemiol 102: 47-54, 1975.
12. Mishina T, Watanabe H, Araki H and Nokao M: Epidemiological study of prostatic cancer by matched pair analysis. Prostate 6: 423-436, 1985. (Pubitemid 15026618)